Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Advanced Solid Tumor 4Solid Tumor 3Advanced Solid Tumors 2Locally Advanced or Metastatic Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Solid Tumor × camrelizumab × Other solid neoplasm × Clear all
NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Beijing Friendship Hospital

Phase 2/3 Completed
172 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05429398 2022-06-23

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Shanghai YingLi Pharmaceutical Co. Ltd.

Phase 1 Unknown
118 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04282278 2021-12-10

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Hebei Medical University Fourth Hospital

Phase 2 Unknown
180 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡